Defining the biomarkers in anti-MRSA fractions of soil Streptomycetes by multivariate analysis
Antonie van Leeuwenhoek · 2025
DOI: 10.1007/s10482-025-02087-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antonie van Leeuwenhoek, 2025. Verfasst von Mohamed Sebak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, UK. mohamed.sebak@pharm.bs…. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Soil Microbiology, Anti-Bacterial Agents, Streptomyces. Die Arbeit nennt 80 Literaturangaben. Gefördert von: Mission Sector, Ministry of Higher Education, Egypt.
Abstract (Originalsprache)
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most alarming antibiotic-resistant pathogens causing nosocomial and community-acquired infections. Actinomycetes, particularly Streptomycetes, have historically been a major source of natural products including anti-MRSA agents. Hence, we designed this study to isolate new anti-MRSA natural products from Streptomycetes aided by liquid chromatography-electrospray ionization-high resolution mass spectrometry (LC-ESI-HRMS)-based metabolomics data analysis and dereplication study to select the best fractions for isolation work. Following this approach, two new natural products, namely, (4-propylphenyl) methane-diazonium (1) and (4E)-6-oxooctadec-4-enoic acid (2) and three known compounds, 8-methyl-5-oxononanoic acid (4), 15-methylhexadecanoic acid (5), and (Z)-14-methylpentadecenoic acid (6) were isolated from two soil Streptomyces sp. Additionally, (9E)-11-hydroxyoctadec-9-enoic acid (3) was recovered for the first time from Streptomycetes. The minimum inhibitory concentration (MIC) of compounds 1, 5, and 6 against MRSA were 128, 64, and 64 µg/mL respectively. The compounds were slightly more active against B. subtilis with MIC values of 64, 64, and 32 µg/mL, respectively. Our research adds to the growing knowledge about the importance of combining sophisticated analytical methods in the chemical profiling of the fractions with the outcomes of the bioassays throughout the subsequent fractionation processes to help isolate new secondary metabolites from natural sources.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Science, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, UK. mohamed.sebak@pharm.bsu.edu.eg.
- Department of Pharmaceutical Microbiology and Immunology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, 62514, Egypt. mohamed.sebak@pharm.bsu.edu.eg.
- Faculty of Science, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, UK.
- Math, Science and Technology Department, University of Minnesota Crookston, Crookston, MN, 56716, USA.
- Department of Pharmaceutical Microbiology and Immunology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, 62514, Egypt.
- Department of Pharmaceutical Microbiology and Immunology, Faculty of Pharmacy, Menofia University, Shebin Elkom, 32511, Egypt.
Förderung
- Mission Sector, Ministry of Higher Education, Egypt
Zitieren
APA
Sebak, M., Mukku, V., Saafan, A. E., Bakeer, W., Abd-ELGhani, S., El-Gendy, A. O., & Edrada-Ebel, R. (2025). Defining the biomarkers in anti-MRSA fractions of soil Streptomycetes by multivariate analysis. Antonie van Leeuwenhoek. https://doi.org/10.1007/s10482-025-02087-8
Vancouver
Sebak M, Mukku V, Saafan AE, Bakeer W, Abd-ELGhani S, El-Gendy AO, et al. Defining the biomarkers in anti-MRSA fractions of soil Streptomycetes by multivariate analysis. Antonie van Leeuwenhoek. 2025. doi:10.1007/s10482-025-02087-8
BibTeX
@article{Sebak2025,
author = {Sebak, Mohamed and Mukku, Venugopal and Saafan, Amal E and Bakeer, Walid and Abd-ELGhani, Sameh and El-Gendy, Ahmed O and Edrada-Ebel, RuAngelie},
title = {Defining the biomarkers in anti-MRSA fractions of soil Streptomycetes by multivariate analysis},
journal = {Antonie van Leeuwenhoek},
year = {2025},
doi = {10.1007/s10482-025-02087-8}
}
EUVIMED